Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.

Expert opinion on biological therapy - 1 Apr 2021

Gotlib Jason, Kluin-Nelemans Hanneke C, Akin Cem, Hartmann Karin, Valent Peter, Reiter Andreas

Abstract excerpt

INTRODUCTION: Systemic mastocytosis (SM) is characterized by the overproduction and accumulation of neoplastic mast cells (MCs) in the bone marrow, skin, and visceral organs. The KIT D816V mutation is found in approximately 90% of cases. In advanced SM (advSM), inferior survival often relates to MC-induced organ damage that may impact multiple organ systems. In addition, mediator symptoms related to MC activation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mastocytosis, Systemic
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Quality of Life

Share to Staurosporine

Source

Identifiers

PMID: 33063554
DOI: 10.1080/14712598.2021.1837109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.PMID 33063554Read ↗

New Insights into the Pathogenesis of Systemic Mastocytosis.Semantic proximity Read ↗

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.Semantic proximity Read ↗

Systemic Mastocytosis: State of the Art.Semantic proximity Read ↗

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.Semantic proximity Read ↗

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read ↗

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Semantic proximity Read ↗

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Semantic proximity Read ↗

Mastocytosis demystified.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.